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CNS lymphoma
To th e E d ito r: Lachance et al1 report results in 10 patients treated according to a standardized protocol with standard-dose cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Several issues can be raised regarding this report. First, patients with neuroradiographically and pathologically documented parenchymal prim ary CNS lymphoma (PCNSL) were evaluated for systemic lymphoma. I am unaware of any studies that demonstrate brain parenchymal métastasés result ing from systemic non-Hodgkin's lymphoma (NHL). Rather, the common pattern of CNS métastasés of systemic NHL is either epidural spinal cord compression or lymphomatous meningitis (LM).2'6 Therefore, I would subm it th at a systemic extent of d isea se e v a lu a tio n is bo th u n n e c e ssa ry and irre le v a n t. However, by contrast, careful staging of the CNS is quite rele vant to treatm en t planning of PCNSL. CNS staging should include slit-lamp examination for possible uveal or vitreous eye disease, CSF cytology for possible lymphomatous meningitis, and spine im ag in g (e ith e r C T -m yelography or co n trastenhanced spine MRI) for possible drop métastasés. Evidence of eye disease necessitates orbital radiotherapy. Positive CSF cytology or a neuroradiographic pattern compatible with LM necessitates either craniospinal irradiation or involved-field radiotherapy and intra-CSF chemotherapy. Spinal drop métas tasés necessitate a treatm ent similar to th at described for lym phomatous meningitis. In the paper by Lachance et al,1 CNS staging of patients with PCNSL appears not to have been uni formly performed and may partially account for the modest out comes reported.
Second, I am unaware of any compelling data to recommend craniospinal irradiation in the adjuvant treatm ent of PCNSL. R adiating the entire neuraxis is associated with m oderate patient morbidity, often resulting in myelosuppression and radi ation enteritis, and may, in addition, compromise the ability to give chem otherapy due to radiation-induced bone marrow injury. Whole-brain or involved-field radiotherapy combined with adjuvant chemotherapy not only obviates the need for craniospinal irradiation but also, as discussed below, results in superior survival outcomes.2,3,5 '9 Third, although CHOP is effective for systemic NHL, it might be expected to be less than effective for PCNSL. Of the four active agents in the CHOP protocol, only cyclophosphamide has demonstrated substantial activity against primary brain tumors-at, however, doses two to three times greater than that employed in CHOP.10 Vincristine and prednisone likely have activity against systemic lymphomas but probably contribute little to regimens directed against CNS tumors. Considerably greater activity and correspondingly improved patient survival have been reported with drug regimens demonstrating substan tial brain parenchym al penetration, such as the high-dose methotrexate/intra-methotrexate/radiotherapy/high-dose ara-C regimen described by DeAngelis et al, the CHAD regimen (cisplatin/high-d o se ara-C /dexam ethasone) described by Mc Laughlin et al, the radiotherapy plus hydroxyurea followed by PCV (procarbazine/CCNU/vincristine) regimen described by Chamberlain and Levin, the high-dose methotrexate regimen of G lasset al, and b lo o d -b ra in -b arrier d isru p tio n regim ens described by Neuwelt et al.7"11 These regimens, which may be equally efficacious a g a in st PCNSL in im m unocom petent patients, result in 40-to 48-month median survival, a substan tial im provem ent over the whole-brain plus CHOP regimen reported by Lachance et al. 1 I believe the ne uro-oncology literature strongly supports the inclusion of adjuvant chemotherapy to involved-field radiothera py in the treatm ent of immunocompetent patients with PCNSL; however, chemotherapy regimens superior to CHOP are avail able and more rationally utilized against these tumors.
M arc C. Chamberlain, MD
La Jolla, CA R e p ly fro m th e A u th o r: We are in agreem ent with Dr. Chamberlain. We certainly do not advocate CHOP as the ideal regimen for primary CNS lymphoma. In fact, our results argue against its use, and we closed this study early because of the high recurrence rate. The point of our paper was the unusual pattern of intracerebral recurrence at apparently uninvolved sites after an initial response at the primary sites.
S. Clifford Schold, Jr., MD Dallas, TX
Cabergoline in Parkinson's disease
To th e E ditor: Lieberman et al1 and Lera et al2 concluded that cabergoline can provide continuous dopaminergic stimulation in patients with Parkinson's disease (PD) when taken orally once a day. It is possible, however, that the improvement after cabergo line-for example, the decrease in "off" time in both studies-is partly due to a peak effect in the morning hours following intake of cabergoline.
Four PD patients participating in an open study of cabergoline in PD with motor fluctuations took cabergoline (mean dose, 8 ± 1.9 mg) at 8 am for 1 week and at 2 pm for another week. All other medications remained the same. These patients kept diaries of their motor function for 2 weeks from 8 am until 11 PM by record ing at half-hour intervals whether they were "on" or "off." We used paired t tests to compare 28 days on which cabergoline was taken at 8 AM with 28 days when the daily intake was at 2 PM. It appears that the timing of cabergoline administration influences the course throughout the day of hours "off' (figure). When cabergoline was taken at 8 am the number of hours "off5 between 8 AM and 2 pm was 1.4 ± 1.0 hours, fewer than the 2.3 ± 1.0 hours recorded when cabergoline was taken at 2 PM (p = 0.000). Intake at 2 pm resulted in 1.4 ± 0.9 hours "off* between 2 PM and 7 pm, fewer than the 2.0 ± 1.1 hours after intake at 
Figure. When cabergoline is adm inistered a t 8 a m (08h), there are fewer hours "off* in the m orning than when cabergoline is taken a t 2 PM (14h). When taken at 2 p m , there are fewer hours "o ff * in the afternoon than when cabergoline is taken a t 8 AM. This suggests th a t there is a peak-dose effect o f cabergoline that does not last throughout the entire day.
goline administration: at 8 am, "off1 = 1.3 ± 0.9 hours; at 2 pm, "off' = 1.4 ± 0.8 hours (p = 0.74), Although the number of subjects is too small to warrant any definite conclusion, our results do suggest a peak-dose effect of cabergoline during the first 5 to 6 hours after administration. This time course matches the course of daily plasma levels of cabergoline (see figure, Lera et al2), showing higher levels 5 to 6 hours after cabergoline intake, especially at the higher dose of 7 mg as taken by our patients.
Lera et al2 reported an improvement of early morning akine sia in all patients, and early morning dystonia practically disap peared. This clearly indicates that cabergoline does exert a longacting dopaminergic effect after the first 5 to 6 hours, but as matters stand at present, further studies will have to be carried out before one can conclude that the easiest way to administer cabergoline (ie, once a day) is also the most effective therapeutic strategy. Despite cabergoline's long-acting properties, adminis tration two or three times a day may prove more beneficial than once daily because the former strategy also implies the benefi cial effects of two or three times a peak-dose effect, especially in higher doses of cabergoline.
M. W .LM . Horst ink H J.C . Berger C.J. W. van de Vlasakker Nijmegen, The Netherlands
Reply from th e Author: The study by Horstink et al is interest ing although limited in size. Cabergoline may be more effective in some patients when given in two divided doses. In the majority of patients in open studies, the convenience of a once-daily dose out weighs the relatively minor benefit of two divided doses.
A braham Lieber man, MD Phoenix, A Z
Reply from th e Authors: The observation of Horstink et al is clearly of great practical interest in the attempt to achieve the best possible therapeutic efficacy for cabergoline. A similar situa tion occurred when pergolide was first experimented with in parkinsonian patients and led to the now-common 3 doses/d application of this dopaminergic agonist. We have observed a sustained motor improvement even after 3 days of stopping cabergoline, and the drug is generally effective in many patients at doses lower than 7 mg/d. We do not believe, therefore, that the observation of Horstink et al is against the idea that cabergoline provides a relatively continuous dopaminergic stimulation. In fact, there is a major problem with their data in that the obser vation is apparently based on patients' diaries rather than direct observation by the investigators. Given the relatively small changes in the time "off' (less than 60 minutes) and the wellknown lack of reliability of patients' self-assessments, the possi bility of a placebo-induced effect should be strongly considered. Beethoven wrote to Wegeler: "For several days Vering has been applying, to both my arms, vesicants consisting of some bark or other-I expect you know what I mean. This is a most unpleasant form of treatment, because it always robs me of the use of my arms for several days-until the bark has taken prop er effect-and is extremely painful to boot. But I m ust admit th at the buzzing and ringing in my ears is now som ew hat fainter, particularly in my left ear. Although so far my hearing has not improved in any way . . . my bowels are now on the mend; when I have taken the lukewarm baths for several days, I feel quite well for a week. . . . Sometimes I take a tonic for my stomach. . . . I am now also following your advice and applying herbs to my belly. . . . Vering won't hear of my taking showerbaths." Beethoven also had the habit of drinking enormous quantities of water, and poured a jug of cold water over his head without drying himself! He felt "hot" at work. He also consulted Johann Adam Schmidt, Johann M alfatti, Rohrich, A ndreas Wawruch, Andreas Bertolini, Jakob Staudenheim (who sent him for balneotherapy in Karlsbad), and Smettana.
Davies4 proposed th at the composer suffered from immunopoietic complications of his inflammatory bowel disease along with alcoholic cirrhosis of the liver and ototoxicity of the chinchona bark (antipyretic). Liston et al5 suggested other causes of his deafness: syphilis, otosclerosis, and P ag et's disease (remember the thickness of the vault of his skull and his huge forehead!).
Beethoven's deafness had no effect on his musical productivi ty and creativity,6,6 but psychologically he became depressed, unhappy, and isolated. Between bouts of depression, he com posed some of his finest material,6 and he wrote: "Let your deaf ness no longer remain a secret-not even in a rt." 6 Like other deaf composers-Rossini and Sibelius-Beethoven
